Silvana Maini
Editorial Director

Abstract

Recent years, like never before, have seen the pharma industry extremely active, with breakthrough research, mergers, acquisitions, partnerships, manufacturing diversification. The USA, Asia and Europe have reached unprecedented quality in the research and development yielded and quality of products and services offered.

In March this year we attended Dcat Week 16 in New York, an internationally-known pharma meeting, where we had the opportunity to speak to several industry players.

The importance of certain hot topics is also shown in the meeting’s final press release, which we show below:

Graham Lewis, vice president, global pharma strategy,
IMS Health, has provided an overview of the global pharmaceutical market and the key trends impacting the market in the program: “Led by the US, an overall compound annual growth rate (CAGR) of 4-7% is projected to 2019, when the global pharmaceutical market is projected to reach $1.3 trillion. The continued resurgence of the US pharmaceutical market with projected CAGR of 6-9% from 2015 to 2019 will lead CAGR in developed markets, which is projected at 4-7% CAGR to 2019, only slightly below the CAGR of 5-8% for pharmerging markets, defined by IMS as the most promising emerging markets, in the forecast period of 2015 to 2019.
A slowing of growth in pharmerging markets and the rise of the US pharmaceutical market will lead the US to account for 45% of global pharmac ... ...